Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EIDP, Inc. Earnings Release 2001

Oct 24, 2001

35588_rns_2001-10-24_cf02d081-8c2d-4a2c-9c8b-261e9829c843.zip

Earnings Release

Open in viewer

Opens in your device viewer

8-K 1 eightokg.htm DUPONT REPORTS THIRD QUARTER 2001 EARNINGS E

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 5(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) October 24, 2001

E. I. du Pont de Nemours and Company

(Exact Name of Registrant as Specified in Its Charter)

Delaware 1-815 51-0014090
(State or Other Jurisdiction (Commission (I.R.S. Employer
Of Incorporation) File Number) Identification No.)

1007 Market Street

Wilmington, Delaware 19898

(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 774-1000

1

Item 5. Other Events

The Registrant Files, pursuant to Regulation FD, its earnings news release dated October 24, 2001, entitled "DuPont Reports Third Quarter 2001 Earnings," a copy of which is below. This earnings news release is also filed in connection with Debt and/or Equity Securities that may be offered on a delayed or continuous basis under Registration Statements on Form S-3 (No. 33-53327, No. 33-61339, No. 33-60069 and No. 333-86363).

October 24, 2001 Clif Webb
WILMINGTON, Del. 302-774-4005
[email protected]

DUPONT REPORTS THIRD QUARTER 2001 EARNINGS

Summary

  • Third quarter 2001 earnings excluding one-time items were $.12 per share, consistent with expectations but below third quarter 2000 earnings of $.51 per share.

  • Lower net income reflects the continuing recession in U.S. manufacturing, resulting in significantly lower volumes and downward pressure on margins. Raw materials costs moderated, resulting in about a $30 million after-tax increase versus third quarter 2000.

  • One-time items in the quarter total a net benefit of $.01 per share, bringing reported earnings per share to $.13.

  • Segment sales in third quarter 2001 of $6.4 billion decreased 14 percent versus third quarter 2000, principally reflecting lower volumes and prices.

  • Worldwide local currency selling prices were down 2 percent. Adverse currency effects, principally from the weaker euro and yen, reduced third quarter worldwide segment sales by 2 percent versus prior year.

  • On October 1, 2001, the company completed the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb Company for $7.8 billion.

Earnings Comparisons

($ per share diluted)

3Q'01 3Q'00
Underlying .12 .51
One-Time Items .01 .02
Reported .13 .53

2

"During the quarter we kept our focus on careful cash management and the actions needed to meet our growth targets over time," said Charles O. Holliday, Jr., DuPont chairman and chief executive officer. "Clearly we are experiencing one of the most challenging business environments the company has faced in decades. DuPont has the financial strength to face this challenge and to continue to invest in the future."

Global Sales and Income

For the quarter, consolidated sales totaled $5.6 billion compared to $6.4 billion in 2000. Segment sales, including transfers and a pro rata share of sales by equity affiliates, were $6.4 billion, down 14 percent from $7.4 billion in 2000. Net income before one-time items was $128 million versus $537 million in 2000. The earnings decline reflects significantly lower results in most of the company's segments, principally due to lower worldwide sales volumes and U.S. dollar margins.

Net income including one-time items was $142 million, compared to earnings of $562 million in the third quarter of 2000.

One-Time Items

One-time items for third quarter 2001 and third quarter 2000 are described in the notes to the accompanying financial statements and are summarized in the table below:

$MM Pretax — 2001 2000 $MM After-Tax — 2001 2000 ($ Per Share) — 2001 2000
Pioneer/Monsanto MON810 Settlement (56) (35) (.04)
Pharmaceuticals Business - Tax Benefit 49 .05
Pioneer Purchase Accounting (50) (55) (.06)
Sale of Interest in Quimica Fluor Affiliate 23 16 .02
Chambers Works Restructuring (28) (17) (.02)
Sale of Stock - DuPont Photomasks, Inc. 123 81 .08
Total - Third Quarter (56) 68 14 25 .01 .02

One-time items include the reserve for a one-time payment made in October 2001 to resolve all issues related to Monsanto YieldGard Ò (MON810 Bt) insect resistant corn trait used in Pioneer's corn hybrids.

Ò Registered trademark of Monsanto.

3

Segment Sales

Regional segment sales and related variances for the third quarter 2001 compared with the third quarter 2000 are summarized below:

Segment Sales — 3Q'01 $B % Change vs. 3Q'00 % Change Due To — Local Price Currency Effect Volume Other *
Worldwide 6.4 (14) (2) (2) (9) (1)
U.S. 3.1 (16) (1) 0 (12) (3)
Europe 1.6 (8) 1 (4) (5) 0
Asia Pacific 1.0 (14) (3) (5) (6) 0
Canada, Mexico, South America 0.7 (13) (5) (1) (7) 0
  • Includes impact of reduced ownership of DuPont Photomasks, Inc. and sale of certain Polyester businesses.

  • Worldwide volumes declined 9 percent. Pharmaceuticals impact on the volume variance versus third quarter 2000 was negligible.

  • U.S. third quarter sales volume was 12 percent lower, reflecting ongoing weakness in the U.S. economy.

  • European volume declined 5 percent. While local currency prices were up 1 percent, the stronger dollar reduced U.S. dollar prices to 3 percent below last year.

  • Asia Pacific sales continue to weaken, down 14 percent, reflecting 6 percent lower volume and 8 percent lower U.S. dollar prices.

Business Segment Performance

The following compares third quarter 2001 results before one-time items for each segment with those for the third quarter 2000.

4

($ in millions) 3Q 2001 2Q 2001 3Q 2000
Coumadin Ò 60 52 80
Sustiva Ô 142 87 99
Cardiolite Ò /Miraluma Ô 62 53 77

Outlook

The company currently expects that the U.S. economy will continue to weaken through the fourth quarter of 2001. The company's macroeconomic outlook for other regional economies, currency, and raw material prices remains consistent with the outlook provided in its second quarter earnings release.

5

The fourth quarter earnings per share outlook for DuPont includes both positives and negatives, as compared to the third quarter:

Positives:

Negatives:

Of these factors, volume and price represent the greatest uncertainty as well as the greatest potential impact on earnings. Consumer and business confidence following the events of September 11 will be critical. Taking all of these issues into account, and acknowledging these uncertainties, the company's current view is that fourth quarter earnings per share will be roughly similar to those in the third quarter.

"Following the tragic events of September 11, our people worldwide have responded with true professionalism in the concern they have shown for the safety and security of our operations and in the attention they have given to our customers and other supply chain partners. The aftermath of September 11 has added to economic uncertainty and will likely prolong the current economic downturn," Holliday said. "I am confident that DuPont has the financial strength, the business focus and operational discipline to meet these new challenges head-on, no matter how long they persist."

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on

6

Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales of agricultural products.

#

10/24/01

NOTE:
http://www.corporate-ir.net/ireye/ir site.zhtml?ticker=DD&script=11948&item id='earnings landing.htm'.

7

E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

CONSOLIDATED INCOME STATEMENT Three Months Ended — September 30 September 30
(Dollars in millions, except per share) 2001 2000 2001 2000
SALES $5,641 $6,445 $19,497 $21,952
Other Income(a) 135 420 521 986
Total 5,776 6,865 20,018 22,938
Cost of Goods Sold and Other Expenses(b) 3,958 4,135 13,059 14,019
Selling, General and Administrative Expenses 687 710 2,269 2,276
Depreciation 328 351 995 1,055
Amortization of Goodwill and Other Intangible Assets 113 113 338 329
Research and Development Expense 441 442 1,288 1,323
Interest and Debt Expense 148 205 492 616
Purchased In-Process Research and Development(c) - - - (11)
Employee Separation Costs and Write-Down of Assets(d) - 28 1,046 126
Gain on Issuance of Stock by Affiliates - Nonoperating(e) - (29) - (29)
Total 5,675 5,955 19,487 19,704
INCOME BEFORE INCOME TAXES AND MINORITY INTERESTS 101 910 531 3,234
Provision for (Benefit from) Income Taxes(f) (46) 339 87 1,133
Minority Interests in Earnings of Consolidated Subsidiaries 5 9 31 48
INCOME BEFORE CUMULATIVE EFFECT OF A CHANGE IN ACCOUNTING PRINCIPLE 142 562 413 2,053
Cumulative Effect of a Change in Accounting Principle, Net of Income Taxes(g) - - 11 -
NET INCOME $ 142 $ 562 $ 424 $ 2,053
BASIC EARNINGS PER SHARE OF COMMON STOCK(h)(i)
Income before Cumulative Effect of a Change in Accounting Principle $ .13 $ .54 $ .39 $ 1.96
Cumulative Effect of a Change in Accounting Principle - - .01 -
Net Income $ .13 $ .54 $ .40 $ 1.96
DILUTED EARNINGS PER SHARE OF COMMON STOCK(h)(i)
Income before Cumulative Effect of a Change in Accounting Principle $ .13 $ .53 $ .39 $ 1.94
Cumulative Effect of a Change in Accounting Principle - - .01 -
Net Income $ .13 $ .53 $ .40 $ 1.94
DIVIDENDS PER SHARE OF COMMON STOCK $ .35 $ .35 $ 1.05 $ 1.05

8

FOOTNOTES TO CONSOLIDATED INCOME STATEMENT

  1. Year-to-date 2001 includes a $52 gain resulting from the Company's sale of stock that reduced its ownership interest in DuPont Photomasks.
  2. Third quarter 2001 includes a charge of $56 to establish a reserve related to settlement of YieldGard® (MON 810 Bt) insect resistant corn litigation with Monsanto. Year-to-date 2001 also includes charges of $133 resulting from the sale of acquired Pioneer inventories which, in accordance with purchase accounting rules, were recorded at fair value on October 1, 1999.
  3. Year-to-date 2000 includes a credit of $11 that was recorded based on revisions of preliminary purchase price allocations associated with the Pioneer acquisition.
  4. Year-to-date 2001 charges of $1,046 include $441 associated with separation costs for approximately 5,500 employees, $303 for asset impairments (principally the write-down of polyester assets), and $302 related to the shutdown and dismantlement of several facilities.
  5. Represents an increase in the Company's equity investment in DuPont Photomasks that resulted from the issuance by DuPont Photomasks of additional shares to unrelated parties at a price in excess of book value.
  6. Third quarter 2001 includes a one-time deferred tax benefit of $49 to recognize differences between the book basis and tax basis of the Company's investment in DuPont Pharmaceuticals as a result of the pending fourth quarter sale of DuPont Pharmaceuticals.
  7. On January 1, 2001, the company adopted SFAS No. 133, "Accounting for Derivative Instruments
  8. Earnings per share are calculated on the basis of the following average number of common shares outstanding:
Three Months Ended — September 30 September 30
Basic Diluted Basic Diluted
2001 1,039,345,016 1,044,530,790 1,041,080,675 1,046,752,988
2000 1,041,269,308 1,047,777,845 1,044,708,476 1,052,825,218

(i) Year-to-date earnings per share do not equal the sum of quarterly earnings per share due to changes in average share calculations.

(j) On October 1, 2001, the Company sold DuPont Pharmaceuticals to Bristol-Myers Squibb for approximately $7,800 in cash. As part of the transaction, the Company retained its interest in Cozaar®/Hyzaar®. The Company estimates this transaction will result in an after-tax gain of about $4,000 in its fourth quarter results.

9

E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

CONSOLIDATED SEGMENT INFORMATION(a) Three Months Ended — September 30 September 30
(Dollars in millions) 2001 2000 2001 2000
SEGMENT SALES (b)
Agriculture & Nutrition $ 546 $ 586 $ 3,601 $ 3,785
Nylon 675 807 2,057 2,360
Performance Coatings & Polymers 1,381 1,572 4,353 4,941
Pharmaceuticals 393 389 902 1,172
Pigments & Chemicals 866 974 2,769 2,972
Polyester 429 594 1,475 1,723
Specialty Fibers 1,060 1,213 3,387 3,813
Specialty Polymers 937 1 ,124 2,985 3,366
Other 67 105 229 371
Total Segment Sales 6,354 7,364 21,758 24,503
Elimination of Intersegment Transfers (111) (165) (384) (501)
Elimination of Equity Affiliate Sales (602) (757) (1,884) (2,055)
Miscellaneous - 3 7 5
CONSOLIDATED SALES $5,641 $6,445 $19,497 $21,952
AFTER-TAX OPERATING INCOME (LOSS) (c)
Agriculture & Nutrition $(153)(d) $ (140)(e) $ 139(f) $ 76(g)
Nylon 25 58 (99) 199
Performance Coatings & Polymers 75 170 224 478(h)
Pharmaceuticals 133(i) 41 79(i) 146
Pigments & Chemicals 112 168(j) 329 518(j)
Polyester (20) 20 (309) 32
Specialty Fibers 65 182 290 600
Specialty Polymers 90 175 273 523
Other (29) 57(k) (33)(l) 63(k)
Total Segment ATOI 298 731 893 2,635
Interest & Exchange Gains and Losses (72) (122) (257) (381)
Corporate Expenses (76) (47)(m) (215) (201)(m)
Corporate Minority Interest(n) (8) - (8) -
INCOME FROM OPERATIONS $142 $ 562 $ 413 $ 2,053

10

FOOTNOTES TO CONSOLIDATED SEGMENT INFORMATION

(a) Certain reclassifications of segment data have been made to reflect second quarter changes in organizational structure. The Agriculture & Nutrition segment now includes the Pioneer business. The Specialty Fibers segment now includes the new Apparel & Textile Sciences SBU, which comprises the former Lycra® business, nylon apparel and specialty textile businesses, and the polyester branded specialties businesses.

  1. Includes pro rata share of equity affiliate sales and intersegment transfers. Excludes sales of intermediates by DuPont to joint ventures within the Nylon and Polyester segments.
  2. Year-to-date 2001 charges of $679 result from employee terminations, facility shutdowns, and asset impairments in the following segments: Agriculture & Nutrition - $80; Nylon - $143; Performance Coatings & Polymers - $60; Pigments & Chemicals - $30; Polyester - $264; Specialty Fibers - $30; Specialty Polymers - $32; and Other - $40.

(d) Includes a charge of $35 to establish a reserve related to settlement of YieldGard® (MON 810 Bt) insect resistant corn litigation with Monsanto.

(e) Includes a charge of $42 for accrued post-employment benefits for Pioneer employees and tax adjustments related to finalization of purchase accounting, as well as a charge of $13 resulting from the sale of acquired Pioneer inventories which, in accordance with purchase accounting rules, were recorded at fair market value on October 1, 1999.

  1. Includes noncash charges of $83 resulting from the sale of acquired Pioneer inventories and the $35 charge to establish a reserve related to settlement of certain Pioneer litigation.
  2. Includes noncash charges of $366 resulting from the sale of acquired Pioneer inventories, a charge of $62 to increase the Company's reserve for Benlate 50 DF fungicide litigation, and a charge of $42 for accrued post-employment benefits for Pioneer employees. These charges were partly offset by a $109 gain resulting from the sale by Pioneer of certain equity securities classified as available for sale, and a credit of $11 to reduce the preliminary purchase price allocated to Pioneer purchased in-process research and development.
  3. Includes a charge of $61 related to separation costs for about 1,000 employees, the shutdown of related manufacturing facilities, and other exist costs.
  4. Includes a deferred tax benefit of $49 to recognize differences between the book basis and tax basis of the Company's investment in DuPont Pharmaceuticals as a result of the pending fourth quarter sale of DuPont Pharmaceuticals.
  5. Includes a charge of $17 resulting from restructuring manufacturing operations at the Chambers Works site, offset by a gain of $16 attributable to the sale of the Company's interest in a Mexican affiliate.
  6. Includes a gain of $62 resulting from the Company's sale of stock that reduced its ownership interest in DuPont Photomasks.
  7. Includes a gain of $34 resulting from the Company's sale of stock that reduced its ownership interest in DuPont Photomasks.
  8. Includes a nonoperating gain of $19 on issuance of stock by affiliates. This represents the increase in the Company's equity investment in DuPont Photomasks that resulted from the issuance by DuPont Photomasks of additional shares to unrelated parties at a price in excess of book value.
  9. Represents a preferred rate of return to a third party investor who contributed capital into a jointly owned company.

11

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

SEGMENT SALES(a)

(3 rd QUARTER 2001 VS. 3 rd QUARTER 2000)

Segment Sales
Three Months Ended Percentage Change Due to:
September 30 U.S.$
$ % Change Price Volume Other(b)
Agriculture & Nutrition $ 546 (7)% (4) (3)
Nylon 675 (16) (3) (13)
Performance Coatings & Polymers 1,381 (12) (3) (9)
Pharmaceuticals 393 1 - 1
Pigments & Chemicals 866 (11) (4) (7)
Polyester 429 (28) (7) (12) (9)
Specialty Fibers 1,060 (13) (4) (9)
Specialty Polymers 937 (17) (3) (14)
Other 67 (36) - - (36)
Total $6,354 (14) (4) (9) (1)

  1. Includes intersegment transfers and pro rata share of equity affiliate sales.

(b) Reflects sales decrease due to divestitures.

SEGMENT INFORMATION — EXCLUDING IMPACT OF ONE-TIME ITEMS - September 30 September 30
(Dollars in millions) 2001 2000 % Chg. 2001 2000 % Chg.
AFTER-TAX OPERATING INCOME (LOSS)
Agriculture & Nutrition $(118) $ (85) N/M $ 337 $ 426 (21)%
Nylon 25 58 (57)% 44 199 (78)
Performance Coatings & Polymers 75 170 (56) 284 539 (47)
Pharmaceuticals 84 41 105 30 146 (79)
Pigments & Chemicals 112 169 (34) 359 519 (31)
Polyester (20) 20 N/M (45) 32 N/M
Specialty Fibers 65 182 (64) 320 600 (47)
Specialty Polymers 90 175 (49) 305 523 (42)
Other (29) (5) N/M (27) 1 N/M
Total Segment ATOI 284 725 (61) 1,607 2,985 (46)
Interest & Exchange Gains and Losses (72) (122) (257) (381)
Corporate Expenses (76) (66) (215) (220)
Corporate Minority Interest (8) - (8) -
INCOME FROM OPERATIONS $ 128 $ 537 (76)% $1,127 $2,384 (53)%

12

E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

FINANCIAL SUMMARY

(Dollars in millions, except per share)

Three Months Ended
September 30 September 30
2001 2000 % Chg. 2001 2000 % Chg.
Selected Income Statement Data -
Excluding Impact of One-Time Items
and Cumulative Effect of a Change
in Accounting Principle
Consolidated Sales $5,641 $6,445 (12)% $19,497 $21,952 (11)%
Segment Sales 6,354 7,364 (14) 21,758 24,503 (11)
Segment ATOI 284 725 (61) 1,607 2,985 (46)
EBIT 319 1,062 (70) 2,251 4,407 (49)
EBITDA 760 1,526 (50) 3,584 5,791 (38)
Income from Operations 128 537 (76) 1,127 2,384 (53)
EPS - Diluted 0.12 0.51 (76) 1.07 2.26 (53)
3 rd Quarter 2001 Vs. September 30, 2001 Vs.
3 rd Quarter 2000 September 30, 2000
Segment ATOI Variance Analysis -
Excluding Impact of One-Time Items
Local Prices $ (80) $ 30
Volume (160) (640)
Costs (125) (615)
Currency (30) (115)
Other (46) (38)
Total $(441) $(1,378)
Six Sigma Estimated Annualized Benefits - $ Pretax
From Ongoing Projects $ 600
From Completed Projects $ 800

13

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E. I. DU PONT DE NEMOURS AND COMPANY
(Registrant)
/s/ D. B. Smith
D. B. Smith
Assistant Controller

October 24, 2001

14